News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Merck & Co., Inc. Unit Held Liable in Australian Vioxx Case
March 5, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Merck & Co's (MRK.N) one-time blockbuster arthritis drug Vioxx doubled the risk of heart attacks and was not fit for sale, an Australian court said on Friday, in a ruling against the U.S. group's Australian unit.
Twitter
LinkedIn
Facebook
Email
Print
Legal
Asia
Australia
Merck & Co.
MORE ON THIS TOPIC
Legal
UPDATE: GSK’s Tesaro Sues AnaptysBio Over Current Jemperli Contract; Anaptys Countersues
November 21, 2025
·
3 min read
·
Tristan Manalac
Drug Development
CRO Boom in APAC region, With China at the Forefront
November 19, 2025
·
5 min read
·
Jennifer Smith-Parker
FDA
Makary Eyes ‘America-First’ User Fee Structure as Renewal Negotiations Approach
November 19, 2025
·
2 min read
·
Tristan Manalac
Collaboration
Lilly Bets More Than $2.6B for South Korea Biotech’s Bispecific Antibody Platform
November 17, 2025
·
2 min read
·
Tristan Manalac
